Open an account

Pfizer

PFE · NYSE

$30.11+$0.67 (+2.28%)TodayMarket closed ·
Prev close $29.44

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.

Employees
75,000
Headquarters
New York City, New York
Listed
Jan 17, 1944
Sector
Health Care
Industry
Pharmaceuticals
Website
pfizer.com

PFE key statistics

Market cap
167.80B
Price-earnings ratio
38.74
Dividend yield
5.86%
Average volume
30.35M
Volume
28.72M
Open price
$29.67
High today
$30.25
Low today
$29.59
52 Week high
$29.88
52 Week low
$23.62

Pfizer (PFE) at a glance

Pfizer (PFE) last traded at $30.11, with a market cap of 167.80B, a price-to-earnings ratio of 38.74 and a dividend yield of 5.86%.

Today the stock has traded between $29.59 and $30.25. The current price is 1.8% above the day's low and 0.5% below its high.

Volume so far is 28.72M shares, in line with the average of 30.35M shares a day.

Over the past year Pfizer has ranged from $23.62 to $29.88, and now sits 104% of the way up that range.

Pfizer met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.77 per share against an estimate of $0.6914.

The average analyst price target is $29.23, 2.9% below the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 15 analyst ratings say Buy
  • Buy40.0%
  • Hold53.3%
  • Sell6.7%
Price target · 31 analystsAvg $29.23
Low
$24.24
Now
$30.11
High
$37.54

PFE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 29.7% on average.

  1. Q3 FY24: reported $1.06 per share against an estimate of $0.6247
  2. Q4 FY24: reported $0.63 per share against an estimate of $0.4754
  3. Q1 FY25: reported $0.92 per share against an estimate of $0.6693
  4. Q2 FY25: reported $0.78 per share against an estimate of $0.5869
  5. Q3 FY25: reported $0.87 per share against an estimate of $0.6397
  6. Q4 FY25: reported $0.66 per share against an estimate of $0.5775
  7. Q1 FY26: reported $0.75 per share against an estimate of $0.7243
  8. Q2 FY26: reported $0.77 per share against an estimate of $0.6914

PFE news

  • Vandana Singh

    Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts

  • Mohd Haider

    JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms

  • Evette Mitkov

    Pfizer Stock Hits 52-Week High: What's Going On?

  • Press releaseBusiness Wire

    Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

  • Ananya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

  • Neeraj Jain

    A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

  • Mohd Haider

    Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’

  • Vandana Singh

    Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease

Similar companies

Companies in the same industry as Pfizer

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.